Learn More
Medchemexpress LLC (2S)-2-[[3-cyclobutyl-5-(3,4,5-trifluorophenoxy)imidazo[4,5-b]pyridin-2-yl]methylamino]propanamide | 1233231-30-5 | 98.3% | 419.4 g/mol | C20H20F3N5O2 | 25MG

Supplier: Medchemexpress LLC HY12507925MG
DSP-2230 (ANP-230) is an orally active voltage-gated sodium channel inhibitor used in preclinical research to modulate Nav1.7, Nav1.8, and Nav1.9 activity and to evaluate approaches for neuropathic pain. The compound is supplied as a solid with characterized solubility profiles and storage recommendations for laboratory use only.
- Inhibits Nav1.7, Nav1.8, and Nav1.9 with reported IC50s of 7.1 μM, 11.4 μM, and 6.7 μM respectively.
- Reported purity 98.33%.
- Soluble in DMSO at ≥100 mg/mL; multiple in vivo formulation protocols with solubility ≥2.25 mg/mL are provided.
- Powder stability: -20°C for up to 3 years; solution stability conditions are reported.
- Intended for preclinical studies of sodium channel pharmacology and neuropathic pain models.
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.